COMPASS PATHWAYS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.95 USD | +0.58% |
|
-4.88% | -19.77% |
| 06-05 | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
| 06-04 | FDA panel to review psychedelic drug MDMA for first time | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 473M | - | - | - | - | - | |
| 59.28B | - | |||||
| 40.94B | ||||||
| 40.17B | ||||||
| 28.69B | ||||||
| 26.63B |
